- Home
- » Tags
- » Benzylpiperazine
Top View
- Federal Register/Vol. 85, No. 47/Tuesday, March 10, 2020/Notices
- 13974/02 JV/Dp 1 DG H II COUNCIL of the EUROPEAN UNION
- Overview of the Major Classes of New Psychoactive Substances
- Comprehensive Forensic Toxicological Analysis of Designer Drugs
- Federal Register/Vol. 78, No. 35/Thursday, February 21, 2013
- N-Benzylpiperazine (BZP)
- List of Scheduling Actions, Controlled Substances And
- The Benzylpiperazine (BZP) / Triflouromethylphenylpiperazine
- N-BENZYLPIPERAZINE (Street Names: BZP, A2, Legal E Or Legal X) December 2019
- Federal Register/Vol. 86, No. 77/Friday, April 23, 2021/Notices
- 6Ar,9S)-Delta-10-THC 1 Cp-LSD 1-(3-Chloro-4-Fluorophenyl
- 2018 Controlled Substance List
- Laboratory Licensure As of July 2003
- Florida Synthetic Drug Scheduling Actions 2011-2014
- Senate Substitute for HOUSE BILL No. 2262
- Federal Register/Vol. 84, No. 190/Tuesday, October 1, 2019
- Introduced 13
- BZP (Benzylpiperazine)
- Drugs of Abuse, a DEA Resource Guide (2020 Edition)
- English-Language Searches) 6
- Critical Review Report: DOC (4-Chloro-2,5-Dimethoxyamfetamine)
- Benzylpiperazine (BZP)
- BZP Fast Facts
- 10-01-20 Phone: 615-741-2650 Rule ID(S): 9404 Email: Publlcall Ons,Information@Tn .Gov File Date: 10/1/2020 Effective Date: 12/30/2020
- December, 2020 (Revised) 1 RULES of TENNESSEE DEPARTMENT of MENTAL HEALTH and SUBSTANCE ABUSE SERVICES OFFICE of LICENSURE CHAPT
- Rules and Regulations
- 87(R) Hb 2593
- Controlled Substances List (Adopted by Alabama State Board of Health on January 15, 2020, Effective January 15, 2020)
- Determining the Subjective Effects of TFMPP in Human Males
- Novel Psychoactive Substances (Designer Drugs): Overview and Pharmacology of Modulators of Monoamine Signalling
- Scheduled Drugs
- Europol–EMCDDA Joint Report on a New Psychoactive Substance: 1-Benzylpiperazine (BZP)
- Drugs of Abuse (2017 Edition)
- BZP and TFMPP at a 3 Mg/Kg Dose (1:1 Ratio) Produced Parallel Increases in 5-HT and DA, Mirroring the Results of MDMA
- Drugs and Medical Devices Group
- Designer Drug (DD) Abuse in Poland; a Review of the Psychoactive And